Go Pro
→ The trade I’ve been waiting for since 2011 (From Traders Agency) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arvinas, Inc. stock logo
ARVN
Arvinas
$8.40
-0.6%		$8.74
$6.97
▼
$14.51
$545.20M1.75576,112 shs1.47 million shs
ProKidney Corp. stock logo
PROK
ProKidney
$1.81
+0.6%		$1.67
$1.30
▼
$3.48
$544.18M1.71.11 million shs952,586 shs
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
$29.71
+2.3%		$32.47
$14.39
▼
$39.53
$567.91M3.31210,754 shs145,002 shs
Theratechnologies Inc. stock logo
THTX
Theratechnologies
$3.42
+0.9%		$3.35
$2.24
▼
$3.40
$157.21M0.51506,857 shs3.27 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arvinas, Inc. stock logo
ARVN
Arvinas
0.00%-10.01%-5.80%+12.82%+9.17%
ProKidney Corp. stock logo
PROK
ProKidney
0.00%-10.45%+35.34%+7.78%-27.42%
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
0.00%-5.53%-16.79%-1.16%+63.94%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
0.00%0.00%0.00%0.00%+3.61%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arvinas, Inc. stock logo
ARVN
Arvinas
$8.40
-0.6%		$8.74
$6.97
▼
$14.51
$545.20M1.75576,112 shs1.47 million shs
ProKidney Corp. stock logo
PROK
ProKidney
$1.81
+0.6%		$1.67
$1.30
▼
$3.48
$544.18M1.71.11 million shs952,586 shs
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
$29.71
+2.3%		$32.47
$14.39
▼
$39.53
$567.91M3.31210,754 shs145,002 shs
Theratechnologies Inc. stock logo
THTX
Theratechnologies
$3.42
+0.9%		$3.35
$2.24
▼
$3.40
$157.21M0.51506,857 shs3.27 million shs
7 Stocks That Will Be Magnificent in 2026 Cover
7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arvinas, Inc. stock logo
ARVN
Arvinas
0.00%-10.01%-5.80%+12.82%+9.17%
ProKidney Corp. stock logo
PROK
ProKidney
0.00%-10.45%+35.34%+7.78%-27.42%
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
0.00%-5.53%-16.79%-1.16%+63.94%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
0.00%0.00%0.00%0.00%+3.61%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arvinas, Inc. stock logo
ARVN
Arvinas
2.27
Hold$14.1768.65% Upside
ProKidney Corp. stock logo
PROK
ProKidney
2.67
Moderate Buy$12.00562.98% Upside
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
2.88
Moderate Buy$77.25160.01% Upside
Theratechnologies Inc. stock logo
THTX
Theratechnologies
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest THTX, PROK, ARVN, and TECX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
9/1/2026
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
Oppenheimer Holdings, Inc. logo
Oppenheimer
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
8/18/2026
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/13/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D)
8/10/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$10.00
8/10/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$14.00
8/10/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$24.00 ➝ $21.00
8/7/2026
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$101.00 ➝ $93.00
8/5/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$11.00 ➝ $12.00
8/5/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/4/2026
Arvinas, Inc. stock logo
ARVN
Arvinas
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$15.00 ➝ $11.00
(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arvinas, Inc. stock logo
ARVN
Arvinas
$262.60M2.06N/AN/A$6.76 per share1.24
ProKidney Corp. stock logo
PROK
ProKidney
$890K614.83N/AN/A($3.36) per share-0.54
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
N/AN/AN/AN/A$13.43 per shareN/A
Theratechnologies Inc. stock logo
THTX
Theratechnologies
$84.38M1.86N/AN/A($0.55) per share-6.22
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arvinas, Inc. stock logo
ARVN
Arvinas
-$80.80M$0.1084.01N/AN/A2.94%1.91%1.29%11/4/2026 (Estimated)
ProKidney Corp. stock logo
PROK
ProKidney
-$68.99M-$0.55N/AN/AN/A-10,288.39%N/A-27.39%11/9/2026 (Estimated)
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
-$74.15M-$4.57N/AN/AN/AN/A-35.26%-33.59%11/5/2026 (Estimated)
Theratechnologies Inc. stock logo
THTX
Theratechnologies
-$8.31M-$0.19N/A48.84N/A-10.85%N/A-9.83%N/A

Latest THTX, PROK, ARVN, and TECX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
ProKidney Corp. stock logo
PROK
ProKidney
-$0.14-$0.15-$0.01-$0.15$0.19 million$0.15 million
8/6/2026Q2 2026
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
-$1.35-$1.18+$0.17-$1.18N/AN/A
8/4/2026Q2 2026
Arvinas, Inc. stock logo
ARVN
Arvinas
-$0.3741$2.58+$2.9541$2.58$60.71 million$249.70 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Arvinas, Inc. stock logo
ARVN
Arvinas
N/AN/AN/AN/AN/A
ProKidney Corp. stock logo
PROK
ProKidney
N/AN/AN/AN/AN/A
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
N/AN/AN/AN/AN/A
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arvinas, Inc. stock logo
ARVN
Arvinas
N/A
7.91
7.91
ProKidney Corp. stock logo
PROK
ProKidney
N/A
8.36
8.36
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
N/A
22.29
22.29
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/A
0.84
0.65

Institutional Ownership

CompanyInstitutional Ownership
Arvinas, Inc. stock logo
ARVN
Arvinas
95.19%
ProKidney Corp. stock logo
PROK
ProKidney
51.59%
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
62.63%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/A

Insider Ownership

CompanyInsider Ownership
Arvinas, Inc. stock logo
ARVN
Arvinas
7.30%
ProKidney Corp. stock logo
PROK
ProKidney
39.83%
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
39.80%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Arvinas, Inc. stock logo
ARVN
Arvinas
24664.52 million59.81 millionOptionable
ProKidney Corp. stock logo
PROK
ProKidney
231302.32 million181.91 millionOptionable
Tectonic Therapeutic, Inc. stock logo
TECX
Tectonic Therapeutic
6019.55 million11.77 millionN/A
Theratechnologies Inc. stock logo
THTX
Theratechnologies
14045.98 millionN/AOptionable

Recent News About These Companies

Theratechnologies Announces Completion of Acquisition by Future Pak
September 25, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/25/3156603/0/en/theratechnologies-announces-completion-of-acquisition-by-future-pak.html
Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak
September 16, 2025  |  financialpost.comF
Theratechnologies Receives Final Court Approval of Proposed Plan of Arrangement to Be Acquired by Future Pak
September 16, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/16/3151254/0/en/theratechnologies-receives-final-court-approval-of-proposed-plan-of-arrangement-to-be-acquired-by-future-pak.html
Theratechnologies shareholders approve proposed acquisition by Future Pak
September 12, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/theratechnologies-shareholders-approve-proposed-acquisition-by-future-pak/ar-AA1MruXH
Theratechnologies Shareholders Approve Acquisition by Future Pak Affiliate
September 12, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/theratechnologies-shareholders-approve-acquisition-by-future-pak-affiliate?utm_source=marketbeat.com&utm_medium=referral
Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak
September 12, 2025  |  financialpost.comF
Theratechnologies Shareholders Approve Proposed Plan of Arrangement to Be Acquired by Future Pak
September 12, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/12/3149314/0/en/theratechnologies-shareholders-approve-proposed-plan-of-arrangement-to-be-acquired-by-future-pak.html
Theratechnologies announces availability of EGRIFTA WR
September 6, 2025  |  msn.comhttps://www.msn.com/en-us/health/other/theratechnologies-announces-availability-of-egrifta-wr/ar-AA1LXQej
Theratechnologies Announces Availability of EGRIFTA WR™ (tesamorelin) for injection to Reduce Excess Abdominal Fat in Adults with HIV and Lipodystrophy
September 5, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/05/3145221/0/en/theratechnologies-announces-availability-of-egrifta-wr-tesamorelin-for-injection-to-reduce-excess-abdominal-fat-in-adults-with-hiv-and-lipodystrophy.html
Theratechnologies Announces Independent Proxy Advisor Firms ISS and Glass Lewis Recommend Shareholders Vote “FOR” the Proposed Plan of Arrangement with Future Pak
September 2, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/09/02/3142543/0/en/theratechnologies-announces-independent-proxy-advisor-firms-iss-and-glass-lewis-recommend-shareholders-vote-for-the-proposed-plan-of-arrangement-with-future-pak.html
Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak
August 18, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/18/3134927/0/en/theratechnologies-announces-filing-of-special-meeting-materials-and-receipt-of-interim-order-in-relation-to-its-acquisition-by-cb-biotechnology-an-affiliate-of-future-pak.html
Theratechnologies Reports Financial Results for the Second Quarter 2025
July 9, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/09/3112459/0/en/theratechnologies-reports-financial-results-for-the-second-quarter-2025.html
Theratechnologies: Beyond GLP-1s - Is Tesamorelin's Exit A Sign Of New Metabolic Opportunities?
July 7, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4799599-theratechnologies-future-pak-acquisition-tesamorelin-exit-new-metabolic-opportunities-glp-1
Future Pak to buy Theratechnologies for $254 million
July 4, 2025  |  thepharmaletter.comT
Theratechnologies Stock (NASDAQ:THTX), Insider Trading Activity
July 3, 2025  |  benzinga.comhttps://www.benzinga.com/quote/THTX/insider-trades
Theratechnologies Inc. (THTX) - Yahoo Finance
July 3, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/THTX/news/
Theratechnologies Stock Short Interest Report | NASDAQ:THTX - Benzinga
July 3, 2025  |  benzinga.comhttps://www.benzinga.com/quote/THTX/short-interest
Theratechnologies shareholders should take the deal, Research Capital says
July 3, 2025  |  cantechletter.comC
Theratechnologies to be bought by CB Biotechnology for $254M
July 3, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/theratechnologies-to-be-bought-by-cb-biotechnology-for-254m/ar-AA1HU9aq
Theratechnologies to Announce Second Quarter 2025 Financial Results
July 3, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/03/3110139/0/en/theratechnologies-to-announce-second-quarter-2025-financial-results.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Arvinas stock logo

Arvinas NASDAQ:ARVN

$8.40 -0.05 (-0.59%)
Closing price 04:00 PM Eastern
Extended Trading
$8.40 +0.00 (+0.06%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

ProKidney stock logo

ProKidney NASDAQ:PROK

$1.81 +0.01 (+0.56%)
Closing price 04:00 PM Eastern
Extended Trading
$1.81 0.00 (-0.06%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Tectonic Therapeutic stock logo

Tectonic Therapeutic NASDAQ:TECX

$29.71 +0.66 (+2.27%)
Closing price 04:00 PM Eastern
Extended Trading
$29.91 +0.20 (+0.67%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

Theratechnologies stock logo

Theratechnologies NASDAQ:THTX

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas